This is where synthetic lethality comes into play: the combination of a BRCA mutation (which impairs HR) and PARP inhibition (which blocks the alternative repair pathway) results in the accumulation of lethal DNA damage, selectively killing cancer cells while sparing normal cells that have a functional HR pathway [10]. Here, PARP1 is linked to cancer.